

### RESEARCH ARTICLES

#### Survey uncovering variations in the management of primary sclerosing cholangitis across Europe

J. Eliasson, B. Lo, C. Scramm, O. Chazouilleres, T. Folseraas, U. Beuers and H. Ytting 100553

#### Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice

R.F. Kunst, D.R. de Waart, F. Wolters, S. Duijst, E.W. Vogels, I. Bolt, J. Verheij, U. Beuers, R.P.J. Oude Elferink and S.F.J. van de Graaf 100573

#### Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma

M.T.A. de Beijer, K. Bezstarosti, R. Luijten, W.A.S. Doff, P.P.C. Boor, R.F.A. Pieterman, R. Bouzid, P.J. Biesta, J.N.M. Ijzermans, M. Doukas, R.A. de Man, A.M. Woltman, J.A.A. Demmers and S.I. Buschow 100576

#### Alpha-1 antitrypsin Pi\*Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease

L. Balcar, B. Scheiner, M. Urheu, P. Weinberger, R. Paternostro, B. Simbrunner, L. Hartl, M. Jachs, D. Bauer, G. Semmler, C. Willheim, M. Pinter, P. Ferenci, M. Trauner, T. Reiberger, A.F. Stättermayer and M. Mandorfer 100562

#### Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis

P.R. Braadland, K.M. Schneider, A. Bergquist, A. Molinaro, A. Lövgren-Sandblom, M. Henricsson, T.H. Karlsen, M. Vesterhus, C. Trautwein, J.R. Hov and H.-U. Marschall 100561

#### Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis

J. Rivera-Esteban, R. Manzano-Nuñez, T. Broquetas, I. Serra-Matamala, O. Bassegoda, A. Soriano-Varela, G. Espín, J. Castillo, J. Bañares, J.A. Carrión, P. Ginès, I. Graupera and J.M. Pericàs 100574

#### XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression

Q. Wang, Q. Bu, M. Liu, R. Zhang, J. Gu, L. Li, J. Zhou, Y. Liang, W. Su, Z. Liu, M. Wang, Z. Lian, L. Lu and H. Zhou 100555

#### Spleen volume-based non-invasive tool for predicting hepatic decompensation in people with compensated cirrhosis (CHESS1701)

Q. Yu, C. Xu, Q. Li, Z. Ding, Y. Lv, C. Liu, Y. Huang, J. Zhou, S. Huang, C. Xia, X. Meng, C. Lu, Y. Li, T. Tang, Y. Wang, Y. Song, X. Qi, J. Ye and S. Ju 100575

#### Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis

D. Overi, G. Carpino, L. Cristoferi, P. Onori, L. Kennedy, H. Francis, N. Zucchini, C. Rigamonti, M. Viganò, A. Floreani, D. D'Amato, A. Gerussi, R. Venere, G. Alpini, S. Glaser, D. Alvaro, P. Invernizzi, E. Gaudio, V. Cardinale and M. Carbone 100556

#### Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis

D. Sierks, R. Schönauer, A. Friedrich, E. Hantmann, J. de Fallois, N. Linder, J. Fischer, A. Herber, C. Bergmann, T. Berg and J. Halbritter 100579

#### Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis

C. Schramm, H. Wedemeyer, A. Mason, G.M. Hirschfield, C. Levy, K.V. Kowdley, P. Milkiewicz, E. Janczewska, E.S. Malova, J. Sanni, P. Koo, J. Chen, S. Choudhury, L.B. Klickstein, M.K. Badman and D. Jones 100544

#### Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis

N. Cazzagon, S. El Mouhadi, Q. Vanderbecq, C. Ferreira, S. Finnegan, S. Lemoine, C. Corpechot, O. Chazouillères and L. Arrivé 100577

#### ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome

M. Biyoukar, C. Corpechot, S. El Mouhadi, E. Chambenois, Q. Vanderbecq, V. Barbu, C. Dong, S. Lemoine, M. Tordjman, R. Jomaah, O. Chazouillères and L. Arrivé 100590

### SHORT COMMUNICATION

#### Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions

S.B. Gressens, D. Cazals-Hatem, V. Lloyd, A. Plessier, A. Payancé, D. Lebecq, F. Durand, G. Socie, D. Valla, V. Paradis, D. Michonneau and P.-E. Rautou 100558

### LETTERS TO THE EDITOR

#### Ammonia rises from the ashes!

N. Weiss and D. Thabut 100559

#### Categorization of differing types of non-tumoral portal vein thrombosis based on the location and hemodynamic changes during liver transplantation

Z. Yang, J. Lerut and S. Zheng 100548

---

### Registration of Clinical Trials

JHEP Reports endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.